World CDx: Market Access for Precision Medicine Summit 2017

RandD pipelines are brimming with targeted therapeutic assets and as testified by the recent PMC study, over 25% of drugs approved last year fall into the precision medicine category. Current focus shifts to the reimbursement and commercial strategy to get ROI and bring these ground-breaking medicines to those in need. It's time for discussion and collaboration between regulatory, reimbursement and market access specialists to ensure drug and diagnostic products reach the right patient at the right cost. The Market Access for Precision Medicine Summit 2017 is here to bring together pharma, biotech, diagnostic developers, regulators and payers, and provide much needed clarity on key regulatory, reimbursement and commercialization challenges facing precision medicine and diagnostic products. Join the likes of GSK, Teva, FDA, Pfizer and Inova Health System.